You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
McKesson
Medtronic
Express Scripts

Last Updated: April 5, 2020

DrugPatentWatch Database Preview

RITUXAN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RITUXAN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rutgers, The State University of New JerseyPhase 2
AstraZenecaPhase 2
JDP Therapeutics, Inc.Phase 2

See all RITUXAN clinical trials

Recent Litigation for RITUXAN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all RITUXAN litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
2018-02-23
2018-01-08

See all RITUXAN litigation

Pharmacology for RITUXAN

Patent Text Search: US Patents for RITUXAN

These patents were identified by searching patent claims

Supplementary Protection Certificates for RITUXAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
93138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
300903 Netherlands   Start Trial PRODUCT NAME: INOTUZUMAB OZOGAMICIN; REGISTRATION NO/DATE: EU/1/17/1200 20170703
LUC00074 Luxembourg   Start Trial PRODUCT NAME: ANTICORPS AFUCOSYLE SE LIANT AU RECEPTEUR ALPHA DE L'INTERLEUKINE-5, EN PARTICULIER LE BENRALIZUMAB OU UN VARIANT THERAPEUTIQUEMENT EQUIVALENT DE CELUI-CI, PROTEGE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/17/1252 20180110
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.